Jenni Ilomaki
Overview
Explore the profile of Jenni Ilomaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
1392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim S, Marquina C, Foster E, Bell J, Ilomaki J
Epilepsia
. 2025 Mar;
PMID: 40067170
Objective: The aim of this study was to compare the risk of seizure, recurrent stroke, fall or fracture, and mortality in individuals prescribed different antiseizure medications (ASMs) following an ischemic...
2.
Abebe T, Ilomaki J, Livori A, Bell J, Morton J, Ademi Z
J Gen Intern Med
. 2025 Mar;
PMID: 40038226
Introduction: Myocardial infarction (MI) imposes a significant health burden to the Australian population. However, detailed economic implication of MI on the Australian healthcare system has not been exhaustively explored. Objective:...
3.
Livori A, Ademi Z, Ilomaki J, Nelson A, Bell J, Morton J
Heart Lung Circ
. 2024 Dec;
33(12):e77-e78.
PMID: 39674664
No abstract available.
4.
Leung M, Turner J, Marquina C, Ilomaki J, Tran T, Bykov K, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2444488.
PMID: 39535796
Importance: The increased use of gabapentinoids has been most pronounced in older people who are also susceptible to hip fractures. Objective: To investigate the overall association between gabapentinoids and the...
5.
Picton L, George J, Bell J, Ilomaki J
Health Sci Rep
. 2024 Nov;
7(11):e70165.
PMID: 39512244
Background And Aims: This Australian population-based study investigated statin intensity after hospitalization for ischemic stroke in a matched cohort of people living with and without dementia. Methods: We identified all...
6.
Lord L, Hew M, Leung M, Morton J, Ilomaki J
Pulm Pharmacol Ther
. 2024 Nov;
:102264.
PMID: 39491231
Background: Long-term changes in medication dispensings post cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation have not been described. Our study aimed to investigate changes in medication use following the...
7.
Grzeskowiak L, Moore V, Hall K, Ilomaki J, Schoenaker D, Lovegrove E, et al.
Med J Aust
. 2024 Sep;
221(7):367-373.
PMID: 39285147
Objectives: To examine patterns in the dispensing of category X medications (Therapeutic Goods Administration categorisation system for prescribing medicines in pregnancy) to women aged 15-49 years in Australia during 2008-2021,...
8.
Tan G, Maro J, Wang S, Toh S, Morton J, Ilomaki J, et al.
Am J Epidemiol
. 2024 Sep;
PMID: 39270669
Most drug repurposing studies using real-world data focused on validating, instead of generating, hypotheses. We used tree-based scan statistics to generate repurposing hypotheses for sodium-glucose cotransporter-2 inhibitors (SGLT2i). We used...
9.
Lord L, Wark P, Hew M, Blakeley B, Steeper M, Kirsa S, et al.
J Psychosom Res
. 2024 Aug;
186:111877.
PMID: 39178579
Objective: People living with cystic fibrosis (PwCF) are at increased risk of mental health conditions. There is little evidence addressing psychotropic medication use in PwCF. This study aimed to estimate...
10.
Jung M, Xia T, Ilomaki J, Pearce C, Aitken A, Nielsen S
Pain Med
. 2024 Aug;
PMID: 39107922
Objective: To examine the predictors of persistent opioid use ('persistence') in people initiating opioids for non-cancer pain in Australian primary care. Design: A retrospective cohort study. Setting: Australian primary care....